AIM ImmunoTech to Participate at M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference
03/10/2021 - 06:55 AM
OCALA, Fla., March 10, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas K. Equels, AIM’s Chief Executive Officer, has been invited to present at the Inaugural Emerging Growth Virtual Conference ,
The conference will take place March 17-19, from 9:00 am to 5:00 pm ET, and feature roundtable discussions with C-suite executives moderated by Maxim Research Analysts, fireside chats with live Q&A, and presentations from hundreds of issuers, both domestically and internationally.
During this virtual conference, AIM ImmunoTech will present along with many other important voices in the health care industry. To attend and access exclusive content, sign up to become an M-Vest member HERE and stay tuned for more updates. The presentation will be available on the investor relations section of AIM's website at https://aimimmuno.com/events-presentations/ .
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus.
Contacts:
Crescendo Communications, LLCaim@crescendo-ir.com
AIM ImmunoTech IncIR@aimimmuno.com
AIM Rankings
#3581 Ranked by Stock Gains
AIM Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Biological Product (except Diagnostic) Manufacturing
Country
US
City
Ocala
About AIM
aim immunotech inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the united states. the company's products include alferon n injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. it is also developing ampligen for the treatment of hepatitis b and hiv, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. aim immunotech inc. has research agreement with the japanese national institute of infectious diseases and shionogi & co., ltd. to test its drug ampligen as an adjuvant therapy for covid-19, the new coronavirus infectious disease caused by sars-cov-2. the company was formerly known as
